Expression and correlation of COX-2 and NUCB1 in colorectal adenocarcinoma

Objective To investigate the expression and correlation of COX-2 and NUCB1 in colorectal adenocarcinoma and adjacent tissues. Methods The expression of COX-2 and NUCB1 and their effects on prognosis were predicted using bioinformatics. Immunohistochemistry was used to identify the expression of two molecules in 56 cases of colorectal adenocarcinoma and the surrounding tissues. The expression of two molecules and their association with clinicopathological variables were examined using the chi-square test. The association between COX-2 and NUCB1 was investigated using the Spearman correlation test. Results The STRING database revealed that COX-2 and NUCB1 were strongly linked. According to the UALCAN and HPA database, COX-2 was upregulated while NUCB1 was downregulated in colorectal adenocarcinoma, both at the protein and gene levels. The OS times for COX-2 and NUCB1 high expression, however, exhibited the same patterns. The rate of positive COX-2 immunohistochemical staining in cancer tissues was 69.64% (39/56), which was significantly higher than the rate in healthy tissues 28.57% (16/56). NUCB1 was expressed positively in cancer tissues at a rate of 64.29% (36/56) compared to just 19.64% (11/56) in neighboring tissues. The positive expression levels of COX-2 and NUCB1 were both closely related to clinical stage, differentiation degree, and lymphatic metastases (P < 0.05). In colorectal cancer, COX-2 and NUCB1 expression were significantly correlated (rs = 0.6312, P < 0.001). Conclusion Both COX-2 and NUCB1 are overexpressed and significantly associated in colorectal adenocarcinoma.

[1]  B. Győrffy,et al.  Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer , 2023, GeroScience.

[2]  Nadezhda T. Doncheva,et al.  The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest , 2022, Nucleic Acids Res..

[3]  Zhaohui S. Qin,et al.  UALCAN: An update to the integrated cancer data analysis platform , 2022, Neoplasia.

[4]  C. Lindskog,et al.  A single–cell type transcriptomics map of human tissues , 2021, Science Advances.

[5]  W. Qiu,et al.  Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5+ colorectal cancer , 2020, Cell Death & Disease.

[6]  K. Yan,et al.  Cyclooxygenase 2 Promotes Proliferation and Invasion in Ovarian Cancer Cells via the PGE2/NF-κB Pathway , 2019, Cell transplantation.

[7]  G. K. Aradhyam,et al.  Molecular evolution guided functional analyses reveals Nucleobindin-1 as a canonical E-box binding protein promoting Epithelial-to-Mesenchymal transition (EMT). , 2019, Biochimica et biophysica acta. Proteins and proteomics.

[8]  Xuedong Zhou,et al.  Staphylococcus aureus induces COX-2-dependent proliferation and malignant transformation in oral keratinocytes , 2019, Journal of oral microbiology.

[9]  Chad J. Creighton,et al.  UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses , 2017, Neoplasia.

[10]  Wen Hu,et al.  [Expression and relationship of Ezh2, Runx3 and caspase-3 in endometrial adenocarcinoma]. , 2011, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[11]  E. Giovannucci,et al.  Cyclooxygenase-2 Expression Is an Independent Predictor of Poor Prognosis in Colon Cancer , 2008, Clinical Cancer Research.

[12]  C. Gilbert,et al.  Nucleobindin Co-Localizes and Associates with Cyclooxygenase (COX)-2 in Human Neutrophils , 2008, PloS one.

[13]  M. Błaszczyńska,et al.  PROSTAGLANDINS AND CANCER , 2005, Gut.

[14]  D. Kerr,et al.  Bevacizumab--current status and future directions. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  Jian-ping Liu,et al.  Relationship between COX-2 expression and clinicopathological features of colorectal cancers. , 2004, Chinese medical journal.

[16]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[17]  Hong Zhang,et al.  Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer , 2002, American Journal of Gastroenterology.

[18]  B. A. Ballif,et al.  Interaction of cyclooxygenases with an apoptosis- and autoimmunity-associated protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Y. Kurosawa,et al.  Induction and natural occurrence of serum nucleosomal DNA in autoimmune MRL/lpr/lpr mice: its relation to apoptosis in the thymus. , 1995, Immunology letters.

[20]  R. Coffey,et al.  Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. , 1994, Gastroenterology.

[21]  K. Titani,et al.  Molecular cloning of nucleobindin, a novel DNA-binding protein that contains both a signal peptide and a leucine zipper structure. , 1992, Biochemical and biophysical research communications.

[22]  In Brief,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[23]  Alexander M. Seifalian,et al.  Role of cyclooxygenase-2 in the angiogenesis of colorectal cancer , 2003, International Journal of Colorectal Disease.